Encorafenib Now Approved for BRAF-Positive Colorectal Cancer Encorafenib Now Approved for BRAF-Positive Colorectal Cancer

The targeted agent encorafenib has been approved by the FDA) for use in BRAF-positive colorectal cancer (CRC). It offers a subgroup of patients with CRC a chemotherapy-free treatment option.FDA Approvals
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news